Answers are grounded in this paper and cite their sources.
In 1998, oncologists got a brand new antitumor drug – irinotecan. It’s been already 18 years since its approval for second-line polychemotherapy of metastatic colorectal cancer. Indications for irinotecan use were significantly expanded since that time; it is now used in combination with other therapeutic agents for first- or second-line treatment of metastatic colorectal cancer, in combination with targeted drugs or separately; there are some studies assessing the use of irinotecan in neoadjuvant therapy. The article describes the history and modern schemes of irinotecan administration in treatment of colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Ivanov et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: